Literature DB >> 11437400

Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study.

D Stockton1, V R Doherty, D H Brewster.   

Abstract

We conducted a national, retrospective population-based cohort study of 705 patients hospitalized with a first diagnosis of dermatomyositis (DM) or polymyositis (PM) during 1982-1996 based on linkage of hospital discharge, cancer registration, and death records in Scotland. Risks of cancer were assessed by calculating standardized incidence ratios (SIR). A first malignancy was diagnosed concurrently or subsequently in 50 patients with DM (SIR 7.7, 95% CI 5.7-10.1), and 40 patients with PM (2.1, 1.5-2.9). Significantly elevated risks were observed for lung, cervix uteri, and ovarian cancer in patients with DM, and for Hodgkin's disease in patients with PM. The excess risk of cancer was highest around the time of diagnosis, and for patients with DM remained high for at least 2 years. Risks were elevated for both sexes but only significantly so for females, and were highest in patients aged 45-74 years at the time of diagnosis for DM and 15-44 for PM. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Year:  2001        PMID: 11437400      PMCID: PMC2363903          DOI: 10.1054/bjoc.2001.1699

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Malignancy and interstitial pneumonitis as fatal complications in dermatomyositis.

Authors:  A Hidano; S Torikai; T Uemura; S Shimizu
Journal:  J Dermatol       Date:  1992-03       Impact factor: 4.005

2.  Quality of Scottish Morbidity Record (SMR) data.

Authors:  K Harley; C Jones
Journal:  Health Bull (Edinb)       Date:  1996-09

3.  Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study.

Authors:  B Sigurgeirsson; B Lindelöf; O Edhag; E Allander
Journal:  N Engl J Med       Date:  1992-02-06       Impact factor: 91.245

4.  Completeness of case ascertainment in a Scottish regional cancer registry for the year 1992.

Authors:  D H Brewster; J Crichton; J C Harvey; G Dawson
Journal:  Public Health       Date:  1997-09       Impact factor: 2.427

5.  High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis.

Authors:  C R Maoz; P Langevitz; A Livneh; Z Blumstein; M Sadeh; I Bank; H Gur; M Ehrenfeld
Journal:  Semin Arthritis Rheum       Date:  1998-04       Impact factor: 5.532

6.  The Scottish Record Linkage System.

Authors:  S Kendrick; J Clarke
Journal:  Health Bull (Edinb)       Date:  1993-03

7.  Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.

Authors:  W H Chow; G Gridley; L Mellemkjaer; J K McLaughlin; J H Olsen; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1995-01       Impact factor: 2.506

8.  The overall and temporal association of cancer with polymyositis and dermatomyositis.

Authors:  D Zantos; Y Zhang; D Felson
Journal:  J Rheumatol       Date:  1994-10       Impact factor: 4.666

9.  Polymyositis-dermatomyositis and malignant lesions: does an association exist?

Authors:  S Lakhanpal; T W Bunch; D M Ilstrup; L J Melton
Journal:  Mayo Clin Proc       Date:  1986-08       Impact factor: 7.616

10.  Elevated cancer incidence in patients with dermatomyositis: a population based study.

Authors:  A Airio; E Pukkala; H Isomäki
Journal:  J Rheumatol       Date:  1995-07       Impact factor: 4.666

View more
  73 in total

1.  Incomplete reporting in a case report of corticosteroids in the treatment of alcohol-induced rhabdomyolysis.

Authors:  Chayan Chakraborti; James W Antoon
Journal:  Mayo Clin Proc       Date:  2012-08       Impact factor: 7.616

2.  Dermatomyositis: analysis of 109 patients surveyed at the Hospital das Clínicas (HCFMUSP), São Paulo, Brazil.

Authors:  Luciena Cegatto Martins Ortigosa; Vitor Manuel Silva dos Reis
Journal:  An Bras Dermatol       Date:  2014 Sep-Oct       Impact factor: 1.896

3.  Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study.

Authors:  Kyoko Motomura; Hiroyuki Yamashita; Saeko Yamada; Yuko Takahashi; Hiroshi Kaneko
Journal:  Rheumatol Int       Date:  2019-08-23       Impact factor: 2.631

Review 4.  [Paraneoplastic autoimmune dermatoses].

Authors:  D Didona; M Hertl
Journal:  Hautarzt       Date:  2021-03-01       Impact factor: 0.751

5.  Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study.

Authors:  Shir Azrielant; Shmuel Tiosano; Abdulla Watad; Naim Mahroum; Aaron Whitby; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 6.  Dermatomyositis and colorectal cancer: a systematic review.

Authors:  Ioannis D Gkegkes; Evelyn E Minis; Christos Iavazzo
Journal:  Ir J Med Sci       Date:  2017-11-22       Impact factor: 1.568

7.  Dermatomyositis as an early manifestation and a significant clinical precursor of lung cancer: report of a rare case and review of the current literature.

Authors:  Tsoukalas Nikolaos; Tolia Maria; Kostakis D Ioannis; Lypas Georgios; Pistamaltzian Nikolaos; Demiri Stamatina; Panopoulos Christos; Koumakis Georgios; Barbounis Vasileios; Efremidis Anna
Journal:  Int J Clin Exp Med       Date:  2013-01-26

8.  Paraneoplastic dermatomyositis as presentation of thymic carcinoma.

Authors:  Andrea Dell'Amore; Nizar Asadi; Guido Caroli; Giampiero Dolci; Alessandro Bini; Franco Stella
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-08-21

9.  Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan.

Authors:  Yi-Ju Chen; Chun-Ying Wu; Yu-Lin Huang; Chang-Bi Wang; Jui-Lung Shen; Yun-Ting Chang
Journal:  Arthritis Res Ther       Date:  2010-04-16       Impact factor: 5.156

Review 10.  Paraneoplastic dermatological manifestation of gastrointestinal malignancies.

Authors:  Lyubomir A Dourmishev; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.